Back to: products

Business Opportunities and Investment Strategies for Global Respiratory Drugs Market 2023-2033

PrintEmail
May 2024 | 189 Pages | From $1,000
Description

The report cover may be different from the image shown.

Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

 

Opportunity and Strategy Analysis
This report focuses on identifying opportunities and strategies for investing in the global respiratory drugs market within the forecast period. It provides a complete analysis of the global market both quantitatively and qualitatively. The quantitative analysis includes market size and revenue data of the total demand, sub-markets, and regional/national levels throughout 2023-2033. Qualitative analysis depicts a full picture of market dynamics and trends including drivers, restraints and challenges, emerging products/market trends, and Porter’s Fiver Forces analysis.

Based on the market data and analysis, the report highlights Increasingly Attractive Segments (IAS) and business opportunities in each segmentation. Moreover, a systematic evaluation of Internal Risks (factors arising within the industry development) and External Risks (factors arising from the surrounding environments) is provided for the respiratory drugs industry and market. All the identified risk factors are measured quantitatively according to GMD’s novel numeric system, i.e. each risk is evaluated with GMD Risk Index Number (GMD RIN) and GMD Risk Intensity Level (GMD RIL). This in-depth risk assessment offers a comprehensive understanding of the current risk factors and their developing trends. Furthermore, this report concludes risk management strategies and Critical Success Factors (CSFs) to help companies make intelligence-based business decisions in the global respiratory drugs industry.

Market Coverage & Overview
The report is based on studies for 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. Considering impact of COVID-19 and regional conflicts such as Russia-Ukraine war, the trend and outlook of global market is forecast in optimistic, balanced, and conservative scenarios. In the balanced view, the global respiratory drugs market is expected to reach $203.4 billion by 2033, growing by 6.6% annually over the coming years.

Segmentation Analysis
Highlighted with 90 tables and 104 figures, this 189-page report represents a 360-degree view on the global market with extensively detailed segmentations Drug Type, Disease, Drug Composition, Formulation, Administration, Distribution Channel, and Region/Country as shown below. Annual revenue 2023-2033 for each segment is included in the report.

By Drug Type
• Anti-Asthmatics & COPD Drugs
• Cough & Cold Preparations
• Pulmonary Hypertension Drugs
• Idiopathic Pulmonary Fibrosis Drugs
• Other Drug Types

By Disease
• Asthma
• COPD
• Allergic Rhinitis
• Cystic Fibrosis
• Pulmonary Hypertension
• Idiopathic Pulmonary Fibrosis
• Other Respiratory Diseases

By Drug Composition
• Stand Alone Drugs
• Combination Drugs

By Formulation
• Dry Powder
• Tablets & Capsules
• Sprays
• Syrups & Solutions

By Administration
• Inhalational Drugs
• Oral Drugs
• Injection Drugs

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
The breakdown of all regional markets by country and the breakdown of each national market by Drug Type, Formulation, and Distribution Channel over the forecast years are also included.

Key Companies
The report also covers the current competitive scenario and profiles key vendors including market leaders and important emerging players. A selection of companies profiled in this report includes:
• Abbott Laboratories
• AstraZenca PLC
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb Company
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Inc.

Reasons to Purchase
• Gain a most comprehensive view on global market with lighting on market outlook, segmentations, dynamics and trends, growth opportunities, risk assessment, critical success factors (CSFs), increasingly attractive segments (IAS), and Porter’s Fiver Forces analysis.
• Access identified business opportunities and benchmarked investment strategies.
• Obtain up-to-date data and valuable insights to create regional and national strategies.
• Take wise actions to mitigate potential risk based on the matrix of systematic risk evaluation.
• Outperform competitors using the latest market data and research discoveries.
• Support internal and external presentations with reliable data and profound analysis.
• Backed up by premium primary and secondary information sources with inputs derived from industry professionals across the value chain.
• Supported by free customer services before and after sales.

Table of Contents

1 Introduction 10
1.1 Industry Definition and Research Scope 10
1.1.1 Industry Definition 10
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of Market Research Methodology 14
1.2.2 Market Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 16
1.2.6 Market Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 Market Overview and Dynamics 22
2.1 Market Size and Forecast 22
2.1.1 Impact of COVID-19 on World Economy 23
2.1.2 Impact of COVID-19 on the Market 27
2.1.3 Impact of Russia-Ukraine Conflict 29
2.1.4 Impact of Israel-Palestine War 31
2.2 Major Growth Drivers 32
2.3 Market Restraints and Challenges 37
2.4 Emerging Opportunities and Market Trends 40
2.5 Porter’s Fiver Forces Analysis 43
3 Segmentation of Global Market by Drug Type 47
3.1 Market Overview by Drug Type 47
3.2 Anti-Asthmatics & COPD Drugs 50
3.3 Cough & Cold Preparations 51
3.4 Pulmonary Hypertension Drugs 52
3.5 Idiopathic Pulmonary Fibrosis Drugs 53
3.6 Other Drug Types 54
4 Segmentation of Global Market by Disease 55
4.1 Market Overview by Disease 55
4.2 Asthma 58
4.3 COPD 59
4.4 Allergic Rhinitis 60
4.5 Cystic Fibrosis 61
4.6 Pulmonary Hypertension 62
4.7 Idiopathic Pulmonary Fibrosis 63
4.8 Other Respiratory Diseases 64
5 Segmentation of Global Market by Drug Composition 65
5.1 Market Overview by Drug Composition 65
5.2 Stand Alone Drugs 68
5.3 Combination Drugs 69
6 Segmentation of Global Market by Formulation 71
6.1 Market Overview by Formulation 71
6.2 Dry Powder 74
6.3 Tablets & Capsules 75
6.4 Sprays 76
6.5 Syrups & Solutions 77
7 Segmentation of Global Market by Administration 78
7.1 Market Overview by Administration 78
7.2 Inhalational Drugs 81
7.3 Oral Drugs 82
7.4 Injection Drugs 83
8 Segmentation of Global Market by Distribution Channel 84
8.1 Market Overview by Distribution Channel 84
8.2 Hospital Pharmacies 87
8.3 Retail Pharmacies 88
8.4 Online Pharmacies 89
9 Segmentation of Global Market by Region 90
9.1 Geographic Market Overview 2023-2033 90
9.2 North America Market 2023-2033 by Country 95
9.2.1 Overview of North America Market 95
9.2.2 U.S. 99
9.2.3 Canada 102
9.2.4 Mexico 104
9.3 European Market 2023-2033 by Country 106
9.3.1 Overview of European Market 106
9.3.2 Germany 110
9.3.3 U.K. 112
9.3.4 France 114
9.3.5 Spain 116
9.3.6 Italy 118
9.3.7 Russia 120
9.3.8 Rest of European Market 122
9.4 Asia-Pacific Market 2023-2033 by Country 124
9.4.1 Overview of Asia-Pacific Market 124
9.4.2 Japan 128
9.4.3 China 131
9.4.4 Australia 133
9.4.5 India 135
9.4.6 South Korea 137
9.4.7 Rest of APAC Region 139
9.5 South America Market 2023-2033 by Country 141
9.5.1 Argentina 145
9.5.2 Brazil 147
9.5.3 Chile 149
9.5.4 Rest of South America Market 151
9.6 MEA Market 2023-2033 by Country 152
9.6.1 UAE 156
9.6.2 Saudi Arabia 158
9.6.3 South Africa 160
9.6.4 Other National Markets 162
10 Competitive Landscape 163
10.1 Overview of Key Vendors 163
10.2 New Product Launch, Partnership, Investment, and M&A 166
10.3 Company Profiles 167
Abbott Laboratories 167
AstraZenca PLC 169
Boehringer Ingelheim GmbH 170
Bristol Myers Squibb Company 171
F. Hoffmann La Roche Ltd. 172
GlaxoSmithKline Plc 173
Merck & Co. Inc. 174
Novartis AG 175
Pfizer Inc. 176
Sanofi 177
Teva Pharmaceutical Industries Ltd. 178
Vertex Pharmaceuticals Inc. 179
11 Investing in Respiratory Drugs Industry: Risk Assessment and Management 180
11.1 Risk Evaluation of Global Market 180
11.2 Critical Success Factors (CSFs) 186
RELATED REPORTS 189

List of Tables:

Table 1. Snapshot of Global Respiratory Drugs Market in Balanced Perspective, 2023-2033 20
Table 2. World Economic Outlook, 2024-2036 24
Table 3. World Economic Outlook, 2022-2024 26
Table 4. Scenarios for Economic Impact of Ukraine Crisis 30
Table 5. Scenarios for Economic Impact of Israel-Palestine War 31
Table 6. World Health Spending by Region, $ bn, 2013-2020 36
Table 7. Main Product Trends and Market Opportunities in Global Respiratory Drugs Market 40
Table 8. Global Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 48
Table 9. Global Respiratory Drugs Market by Disease, 2023-2033, $ mn 56
Table 10. Global Respiratory Drugs Market by Drug Composition, 2023-2033, $ mn 66
Table 11. Combinational Therapies 70
Table 12. Global Respiratory Drugs Market by Formulation, 2023-2033, $ mn 72
Table 13. Global Respiratory Drugs Market by Administration, 2023-2033, $ mn 79
Table 14. Global Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 85
Table 15. Global Respiratory Drugs Market by Region, 2023-2033, $ mn 92
Table 16. Leading National Respiratory Drugs Market, 2023 and 2033, $ mn 94
Table 17. North America Respiratory Drugs Market by Country, 2023-2033, $ mn 97
Table 18. U.S. Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 101
Table 19. U.S. Respiratory Drugs Market by Formulation, 2023-2033, $ mn 101
Table 20. U.S. Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 101
Table 21. Canada Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 103
Table 22. Canada Respiratory Drugs Market by Formulation, 2023-2033, $ mn 103
Table 23. Canada Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 103
Table 24. Mexico Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 105
Table 25. Mexico Respiratory Drugs Market by Formulation, 2023-2033, $ mn 105
Table 26. Mexico Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 105
Table 27. Europe Respiratory Drugs Market by Country, 2023-2033, $ mn 108
Table 28. Germany Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 111
Table 29. Germany Respiratory Drugs Market by Formulation, 2023-2033, $ mn 111
Table 30. Germany Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 111
Table 31. U.K. Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 113
Table 32. U.K. Respiratory Drugs Market by Formulation, 2023-2033, $ mn 113
Table 33. U.K. Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 113
Table 34. France Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 115
Table 35. France Respiratory Drugs Market by Formulation, 2023-2033, $ mn 115
Table 36. France Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 115
Table 37. Spain Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 117
Table 38. Spain Respiratory Drugs Market by Formulation, 2023-2033, $ mn 117
Table 39. Spain Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 117
Table 40. Italy Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 119
Table 41. Italy Respiratory Drugs Market by Formulation, 2023-2033, $ mn 119
Table 42. Italy Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 119
Table 43. Russia Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 121
Table 44. Russia Respiratory Drugs Market by Formulation, 2023-2033, $ mn 121
Table 45. Russia Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 121
Table 46. Respiratory Drugs Market in Rest of Europe by Country, 2023-2033, $ mn 123
Table 47. APAC Respiratory Drugs Market by Country, 2023-2033, $ mn 126
Table 48. Japan Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 130
Table 49. Japan Respiratory Drugs Market by Formulation, 2023-2033, $ mn 130
Table 50. Japan Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 130
Table 51. China Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 132
Table 52. China Respiratory Drugs Market by Formulation, 2023-2033, $ mn 132
Table 53. China Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 132
Table 54. Australia Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 134
Table 55. Australia Respiratory Drugs Market by Formulation, 2023-2033, $ mn 134
Table 56. Australia Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 134
Table 57. India Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 136
Table 58. India Respiratory Drugs Market by Formulation, 2023-2033, $ mn 136
Table 59. India Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 136
Table 60. South Korea Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 138
Table 61. South Korea Respiratory Drugs Market by Formulation, 2023-2033, $ mn 138
Table 62. South Korea Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 138
Table 63. Respiratory Drugs Market in Rest of APAC by Country/Region, 2023-2033, $ mn 140
Table 64. South America Respiratory Drugs Market by Country, 2023-2033, $ mn 143
Table 65. Argentina Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 146
Table 66. Argentina Respiratory Drugs Market by Formulation, 2023-2033, $ mn 146
Table 67. Argentina Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 146
Table 68. Brazil Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 148
Table 69. Brazil Respiratory Drugs Market by Formulation, 2023-2033, $ mn 148
Table 70. Brazil Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 148
Table 71. Chile Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 150
Table 72. Chile Respiratory Drugs Market by Formulation, 2023-2033, $ mn 150
Table 73. Chile Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 150
Table 74. MEA Respiratory Drugs Market by Country, 2023-2033, $ mn 154
Table 75. UAE Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 157
Table 76. UAE Respiratory Drugs Market by Formulation, 2023-2033, $ mn 157
Table 77. UAE Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 157
Table 78. Saudi Arabia Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 159
Table 79. Saudi Arabia Respiratory Drugs Market by Formulation, 2023-2033, $ mn 159
Table 80. Saudi Arabia Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 159
Table 81. South Africa Respiratory Drugs Market by Drug Type, 2023-2033, $ mn 161
Table 82. South Africa Respiratory Drugs Market by Formulation, 2023-2033, $ mn 161
Table 83. South Africa Respiratory Drugs Market by Distribution Channel, 2023-2033, $ mn 161
Table 84. Abbott Laboratories: Company Snapshot 167
Table 85. Abbott Laboratories: Business Segmentation 168
Table 86. Abbott Laboratories: Product Portfolio 168
Table 87. List of Risk Factors and Weight Percentages/Theoretical Maximum 181
Table 88. Definition of GMD Relative Risk Index Number (Relative RIN) and GMD Risk Intensity Level (RIL) 182
Table 89. Risk Evaluation for Investing in Global Market, 2023-2033 183
Table 90. Critical Success Factors and Key Takeaways 187

List of Figures:

Figure 1. Research Method Flow Chart 14
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 17
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033 19
Figure 4. Global Respiratory Drugs Market, 2023-2033, $ mn 22
Figure 5. Impact of COVID-19 on Business 27
Figure 6. Primary Drivers and Impact Factors of Global Respiratory Drugs Market 32
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 35
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 35
Figure 9. Primary Restraints and Impact Factors of Global Respiratory Drugs Market 37
Figure 10. Porter’s Fiver Forces Analysis of Global Respiratory Drugs Market 43
Figure 11. Growth Opportunity Analysis by Drug Type 47
Figure 12. Breakdown of Global Respiratory Drugs Market by Drug Type, 2023-2033, % of Revenue 48
Figure 13. Global Addressable Market Cap in 2024-2033 by Drug Type, Value ($ mn) and Share (%) 49
Figure 14. Global Respiratory Drugs Market by Drug Type: Anti-Asthmatics & COPD Drugs, 2023-2033, $ mn 50
Figure 15. Global Respiratory Drugs Market by Drug Type: Cough & Cold Preparations, 2023-2033, $ mn 51
Figure 16. Global Respiratory Drugs Market by Drug Type: Pulmonary Hypertension Drugs, 2023-2033, $ mn 52
Figure 17. Global Respiratory Drugs Market by Drug Type: Idiopathic Pulmonary Fibrosis Drugs, 2023-2033, $ mn 53
Figure 18. Global Respiratory Drugs Market by Drug Type: Other Drug Types, 2023-2033, $ mn 54
Figure 19. Growth Opportunity Analysis by Disease 55
Figure 20. Breakdown of Global Respiratory Drugs Market by Disease, 2023-2033, % of Sales Revenue 56
Figure 21. Global Addressable Market Cap in 2024-2033 by Disease, Value ($ mn) and Share (%) 57
Figure 22. Global Respiratory Drugs Market by Disease: Asthma, 2023-2033, $ mn 58
Figure 23. Global Respiratory Drugs Market by Disease: COPD, 2023-2033, $ mn 59
Figure 24. Global Respiratory Drugs Market by Disease: Allergic Rhinitis, 2023-2033, $ mn 60
Figure 25. Global Respiratory Drugs Market by Disease: Cystic Fibrosis, 2023-2033, $ mn 61
Figure 26. Global Respiratory Drugs Market by Disease: Pulmonary Hypertension, 2023-2033, $ mn 62
Figure 27. Global Respiratory Drugs Market by Disease: Idiopathic Pulmonary Fibrosis, 2023-2033, $ mn 63
Figure 28. Global Respiratory Drugs Market by Disease: Other Respiratory Diseases, 2023-2033, $ mn 64
Figure 29. Growth Opportunity Analysis by Drug Composition 65
Figure 30. Breakdown of Global Respiratory Drugs Market by Drug Composition, 2023-2033, % of Sales Revenue 66
Figure 31. Global Addressable Market Cap in 2024-2033 by Drug Composition, Value ($ mn) and Share (%) 67
Figure 32. Global Respiratory Drugs Market by Drug Composition: Stand Alone Drugs, 2023-2033, $ mn 68
Figure 33. Global Respiratory Drugs Market by Drug Composition: Combination Drugs, 2023-2033, $ mn 69
Figure 34. Growth Opportunity Analysis by Formulation 71
Figure 35. Breakdown of Global Respiratory Drugs Market by Formulation, 2023-2033, % of Revenue 72
Figure 36. Global Addressable Market Cap in 2024-2033 by Formulation, Value ($ mn) and Share (%) 73
Figure 37. Global Respiratory Drugs Market by Formulation: Dry Powder, 2023-2033, $ mn 74
Figure 38. Global Respiratory Drugs Market by Formulation: Tablets & Capsules, 2023-2033, $ mn 75
Figure 39. Global Respiratory Drugs Market by Formulation: Sprays, 2023-2033, $ mn 76
Figure 40. Global Respiratory Drugs Market by Formulation: Syrups & Solutions, 2023-2033, $ mn 77
Figure 41. Growth Opportunity Analysis by Administration 78
Figure 42. Breakdown of Global Respiratory Drugs Market by Administration, 2023-2033, % of Revenue 79
Figure 43. Global Addressable Market Cap in 2024-2033 by Administration, Value ($ mn) and Share (%) 80
Figure 44. Global Respiratory Drugs Market by Administration: Inhalational Drugs, 2023-2033, $ mn 81
Figure 45. Global Respiratory Drugs Market by Administration: Oral Drugs, 2023-2033, $ mn 82
Figure 46. Global Respiratory Drugs Market by Administration: Injection Drugs, 2023-2033, $ mn 83
Figure 47. Growth Opportunity Analysis by Distribution Channel 84
Figure 48. Breakdown of Global Respiratory Drugs Market by Distribution Channel, 2023-2033, % of Revenue 85
Figure 49. Global Addressable Market Cap in 2024-2033 by Distribution Channel, Value ($ mn) and Share (%) 86
Figure 50. Global Respiratory Drugs Market by Distribution Channel: Hospital Pharmacies, 2023-2033, $ mn 87
Figure 51. Global Respiratory Drugs Market by Distribution Channel: Retail Pharmacies, 2023-2033, $ mn 88
Figure 52. Global Respiratory Drugs Market by Distribution Channel: Online Pharmacies, 2023-2033, $ mn 89
Figure 53. Global Market Snapshot by Region 90
Figure 54. Growth Opportunity Analysis of Global Market by Region 91
Figure 55. Geographic Spread of Worldwide Respiratory Drugs Market, 2023-2033, % of Sales Revenue 92
Figure 56. Global Addressable Market Cap in 2024-2033 by Region, Value ($ mn) and Share (%) 93
Figure 57. North American Respiratory Drugs Market, 2023-2033, $ mn 96
Figure 58. Growth Opportunity Analysis of North America Market by Country 96
Figure 59. Breakdown of North America Respiratory Drugs Market by Country, 2023 and 2033, % of Revenue 97
Figure 60. Contribution to North America 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 98
Figure 61. U.S. Respiratory Drugs Market, 2023-2033, $ mn 100
Figure 62. Canada Respiratory Drugs Market, 2023-2033, $ mn 102
Figure 63. Respiratory Drugs Market in Mexico, 2023-2033, $ mn 104
Figure 64. European Respiratory Drugs Market, 2023-2033, $ mn 107
Figure 65. Growth Opportunity Analysis of Europe Market by Country 107
Figure 66. Breakdown of European Respiratory Drugs Market by Country, 2023 and 2033, % of Revenue 108
Figure 67. Contribution to Europe 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 109
Figure 68. Respiratory Drugs Market in Germany, 2023-2033, $ mn 110
Figure 69. Respiratory Drugs Market in U.K., 2023-2033, $ mn 112
Figure 70. Respiratory Drugs Market in France, 2023-2033, $ mn 114
Figure 71. Respiratory Drugs Market in Spain, 2023-2033, $ mn 116
Figure 72. Respiratory Drugs Market in Italy, 2023-2033, $ mn 118
Figure 73. Respiratory Drugs Market in Russia, 2023-2033, $ mn 120
Figure 74. Respiratory Drugs Market in Rest of Europe, 2023-2033, $ mn 122
Figure 75. Asia-Pacific Respiratory Drugs Market, 2023-2033, $ mn 125
Figure 76. Growth Opportunity Analysis of Asia-Pacific Market by Country 125
Figure 77. Breakdown of APAC Respiratory Drugs Market by Country, 2023 and 2033, % of Revenue 126
Figure 78. Contribution to APAC 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 127
Figure 79. Respiratory Drugs Market in Japan, 2023-2033, $ mn 129
Figure 80. Respiratory Drugs Market in China, 2023-2033, $ mn 131
Figure 81. Respiratory Drugs Market in Australia, 2023-2033, $ mn 133
Figure 82. Respiratory Drugs Market in India, 2023-2033, $ mn 135
Figure 83. Respiratory Drugs Market in South Korea, 2023-2033, $ mn 137
Figure 84. Respiratory Drugs Market in Rest of APAC, 2023-2033, $ mn 139
Figure 85. South America Respiratory Drugs Market, 2023-2033, $ mn 142
Figure 86. Growth Opportunity Analysis of South America Market by Country 142
Figure 87. Breakdown of South America Respiratory Drugs Market by Country, 2023 and 2033, % of Revenue 143
Figure 88. Contribution to South America 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 144
Figure 89. Respiratory Drugs Market in Argentina, 2023-2033, $ mn 145
Figure 90. Respiratory Drugs Market in Brazil, 2023-2033, $ mn 147
Figure 91. Respiratory Drugs Market in Chile, 2023-2033, $ mn 149
Figure 92. Respiratory Drugs Market in Rest of South America, 2023-2033, $ mn 151
Figure 93. Respiratory Drugs Market in Middle East and Africa (MEA), 2023-2033, $ mn 153
Figure 94. Growth Opportunity Analysis of MEA Market by Country 153
Figure 95. Breakdown of MEA Respiratory Drugs Market by Country, 2023 and 2033, % of Revenue 154
Figure 96. Contribution to MEA 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 155
Figure 97. Respiratory Drugs Market in UAE, 2023-2033, $ mn 156
Figure 98. Respiratory Drugs Market in Saudi Arabia, 2023-2033, $ mn 158
Figure 99. Respiratory Drugs Market in South Africa, 2023-2033, $ mn 160
Figure 100. Respiratory Drugs Market in the Rest of MEA, 2023-2033, $ mn 162
Figure 101. Growth Stage of Global Respiratory Drugs Industry over the Forecast Period 163
Figure 102. Comparison of Risk Factors by GMD RIN in 2023 183
Figure 103. GMD Relative RIN of Internal Risk Factors in 2023 on Radar Chart 184
Figure 104. GMD Relative RIN of External Risk Factors in 2023 on Radar Chart 184

Reviews

There are yet no reviews for this product.